The pattern of repeated late filings, combined with a $3M market cap and prior asset foreclosure, points to a company that may be unable to continue as a going concern. Monitor for the actual 10-Q filing within the 5-day extension window; if it reveals further deterioration or a going concern qualification, the stock could face delisting or bankruptcy proceedings.
KALA drugs
KALA drug pipeline →Price Chart
Executive Summary
KALA BIO filed a late notification (NT 10-Q) for its quarterly report for the period ended September 30, 2026, citing the need for additional time to complete analysis and disclosure regarding its liquidity and capital resources. This is the company's third consecutive late filing (following NT 10-K and NT 10-Q in the prior year), and the company has a market cap of only $3M, indicating severe financial distress. The filing does not mention any restatement or auditor change.
Key Financial Metrics
Key Facts
- Filed NT 10-Q for period ended September 30, 2026 on November 13, 2026
- Reason: additional time needed to complete analysis and disclosure regarding liquidity and capital resources
- Anticipates filing within 5 calendar days of prescribed due date
- This is the third late filing in approximately 12 months (prior NT 10-K filed March 31, 2026 and NT 10-Q filed November 14, 2025)
- Market cap is $3M, indicating near-zero equity value
- No mention of restatement or auditor change in the filing
- Company previously disclosed lender foreclosure on all assets and termination of employees in October 2025
Financial Impact
Market cap of $3M; company previously had all assets foreclosed by lender Oxford Finance LLC in October 2025
Risk Factors
- Potential Nasdaq delisting for failure to file timely periodic reports
- Going concern risk given $3M market cap and prior asset foreclosure
- Possible further asset liquidation or bankruptcy filing
- No auditor change or restatement mentioned, but chronic late filings suggest systemic accounting/resourcing issues
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| NT 10-Q Filing (Primary) | 0001829126-26-012407 |
| Document: 0001829126-26-012407-index-headers.html | 0001829126-26-012407 |
| Document: 0001829126-26-012407-index.html | 0001829126-26-012407 |
| Document: 0001829126-26-012407.txt | 0001829126-26-012407 |
Track record
10 reports on KALA
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +77.78% at T+60 after the Jun 26, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Viewing Entry $0.1496 Now $0.1390 +7.09% settles Nov 17
- Nov 12, 20264d ago 8-K Bearish 5/10 Entry $0.1388 to $0.1277 Now $0.1390 −0.14% ▲ +8.02% +6.11% vs SPY
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1773 to $0.1710 Now $0.1390 −21.60% ▼ −3.55% −3.19% vs SPY
- Oct 19, 202628d ago SC 13G Neutral 3/10 Entry $0.1926 to $0.1897 Now $0.1390 −27.83% ▼ −1.51% −1.84% vs SPY
- Sep 24, 20267w ago Press Release Neutral 3/10 Entry $0.5600 to $0.4760 Now $0.1390 −75.18% ▼ −15.00% −15.54% vs SPY
- Aug 28, 202611w ago 8-K Bearish 8/10 Entry $0.6901 to $0.6727 Now $0.1390 +79.86% ▲ +2.52% +2.22% vs SPY
- Jul 22, 202616w ago 424B5 Bearish 8/10 Entry $0.6103 to $0.6342 Now $0.1390 +77.22% ▼ −3.92% −3.81% vs SPY
- Jun 26, 202620w ago EFFECT Bearish 7/10 Entry $2.52 to $2.09 Now $0.1390 +94.48% ▲ +17.06% +18.71% vs SPY
- May 7, 202627w ago S-3 Neutral 2/10 Entry $3.95 to $3.91 Now $0.1390 −96.48% ▼ −1.01% −1.24% vs SPY
- Mar 4, 202636w ago Press Release Mixed 6/10 Entry $17.25 to $0.2750 Now $0.1390 −99.19% ▼ −98.41% −97.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers